lisofylline has been researched along with Hematologic Malignancies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, F; Bianco, JA; Dahlberg, S; Jansen, J; Karanes, C; Kirkhart, B; Liesveld, J; List, AF; Litzow, M; Maziarz, R; Schuster, M; Singer, JW; Stiff, P; Wolff, S | 1 |
1 trial(s) available for lisofylline and Hematologic Malignancies
| Article | Year |
|---|---|
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Bone Marrow Transplantation; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Evaluation Studies as Topic; Female; Graft vs Host Disease; Hematologic Neoplasms; HLA Antigens; Humans; Infections; Male; Middle Aged; Nuclear Family; Pentoxifylline; Placebos; Recurrence; Survival Rate; Time Factors; Tissue Donors; Transplantation, Homologous; Whole-Body Irradiation | 2000 |